Shares of Flexion Therapeutics Inc. (FLXN) - Get Flexion Therapeutics, Inc. Report soared 17.8% to $31.94 on Friday, Oct. 6, after the Burlington, Mass.-based firm received approval from the U.S. Food and Drug Administration for osteoarthritis knee pain treatment Zilretta.

"We believe that Zilretta has the potential to be a transformative medicine for the more than five million patients who receive an intra-articular injection for OA knee pain each year," said Flexion president and CEO Michael Clayman, M.D., in a statement.

Zilretta is a non-opioid medicine utilizing Flexion's microsphere technology.

Flexion said it expects the medicine to be available in the U.S. by the end of the month.

TheStreet Recommends

More of What's Trending on TheStreet: